MedPath

Lorazepam

Generic Name
Lorazepam
Brand Names
Ativan, Loreev
Drug Type
Small Molecule
Chemical Formula
C15H10Cl2N2O2
CAS Number
846-49-1
Unique Ingredient Identifier
O26FZP769L
Background

Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.

Indication

Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.

Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.

Associated Conditions
Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus
Associated Therapies
Anesthetic premedication therapy

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

Phase 2
Active, not recruiting
Conditions
Advanced Cancers
Interventions
Drug: Placebo
Behavioral: Questionnaires
First Posted Date
2013-09-24
Last Posted Date
2025-01-29
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
93
Registration Number
NCT01949662
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sedative Premedication: Efficacy On Patient Experience

Phase 3
Completed
Conditions
Perioperative Anxiety
Interventions
Other: no premedication
Drug: Placebo (microcrystalline celluloses)
First Posted Date
2013-07-17
Last Posted Date
2015-04-21
Lead Sponsor
Assistance Publique Hopitaux De Marseille
Target Recruit Count
1200
Registration Number
NCT01901003
Locations
🇫🇷

Assistance Publique Hopitaux de Marseille, Marseille, France

Characterizing and Predicting Drug Effects on Cognition

Phase 4
Completed
Conditions
Cognitive Deficits
Interventions
First Posted Date
2013-06-28
Last Posted Date
2019-12-17
Lead Sponsor
University of Minnesota
Target Recruit Count
60
Registration Number
NCT01889602
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

ADASUVE-Lorazepam Drug-Drug Interaction

Phase 4
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Inhaled Placebo
Drug: Placebo IM
First Posted Date
2013-06-14
Last Posted Date
2017-12-13
Lead Sponsor
Alexza Pharmaceuticals, Inc.
Target Recruit Count
22
Registration Number
NCT01877642
Locations
🇺🇸

Covance-Evansville, Evansville, Indiana, United States

Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus

Phase 3
Completed
Conditions
Status Epilepticus
Epilepsy
Interventions
First Posted Date
2013-06-05
Last Posted Date
2018-10-11
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
434
Registration Number
NCT01870024
Locations
🇫🇷

Département d'Anesthésie - Réanimation - SMUR - Hôpital Lariboisière, Paris, France

Promethazine vs. Lorazepam for Treatment of Vertigo

Phase 3
Completed
Conditions
Peripheral Vertigo.
Interventions
First Posted Date
2013-04-09
Last Posted Date
2013-06-14
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Target Recruit Count
210
Registration Number
NCT01827293
Locations
🇮🇷

Department of Neurology, Emam Hossein Hospital, Tehran, Nezam Abad, Iran, Islamic Republic of

Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)

Completed
Conditions
Alpha-1 Antitrypsin Deficiency
Liver Fibrosis
AAT Deficiency
AATD
Interventions
Device: Abdominal ultrasound
Procedure: History and physical
Procedure: Intravenous catheter
Procedure: Blood draw
Other: Liver questionnaire
Procedure: Liver Biopsy
Drug: Oxycodone/Acetaminophen
First Posted Date
2013-03-13
Last Posted Date
2023-08-21
Lead Sponsor
University of Florida
Target Recruit Count
109
Registration Number
NCT01810458
Locations
🇺🇸

Shands at the University of Florida, Gainesville, Florida, United States

Glutamatergic Modulation of Cocaine-related Deficits

Phase 2
Completed
Conditions
Cocaine Dependence
Interventions
First Posted Date
2013-02-13
Last Posted Date
2019-04-30
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
8
Registration Number
NCT01790490
Locations
🇺🇸

NYSPI, New York, New York, United States

The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms

Phase 1
Completed
Conditions
Alzheimer's Disease (AD)
Interventions
First Posted Date
2013-01-31
Last Posted Date
2016-11-10
Lead Sponsor
Mayo Clinic
Target Recruit Count
57
Registration Number
NCT01780519
Locations
🇺🇸

Mayo Clinic, Scottsdale, Arizona, United States

Explanation About Sleep in Post Trauma Patients

Not Applicable
Conditions
Post Traumatic Stress Disorder
Sleep Deprivation
Interventions
Behavioral: Explanation encouraging sleep
Behavioral: Explanation discouraging sleep
First Posted Date
2012-09-12
Last Posted Date
2012-10-10
Lead Sponsor
Sheba Medical Center
Target Recruit Count
70
Registration Number
NCT01684085
Locations
🇮🇱

Chaim Sheba Medical Center, Tel Hashomer, Israel

© Copyright 2025. All Rights Reserved by MedPath